News stories about Akcea Therapeutics (NASDAQ:AKCA) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Akcea Therapeutics earned a daily sentiment score of 0.08 on Accern’s scale. Accern also gave news headlines about the company an impact score of 46.3917993349092 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
AKCA has been the topic of a number of recent analyst reports. Zacks Investment Research raised Akcea Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, November 9th. Stifel Nicolaus reissued a “buy” rating and issued a $20.00 price objective (up previously from $19.00) on shares of Akcea Therapeutics in a research note on Tuesday, November 7th. BidaskClub raised Akcea Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, January 20th. Finally, Cowen reaffirmed a “buy” rating on shares of Akcea Therapeutics in a research note on Tuesday, October 31st. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $22.75.
Akcea Therapeutics (AKCA) opened at $23.00 on Thursday. Akcea Therapeutics has a one year low of $8.10 and a one year high of $31.23.
COPYRIGHT VIOLATION WARNING: This story was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/15/akcea-therapeutics-akca-receives-coverage-optimism-score-of-0-08.html.
About Akcea Therapeutics
Akcea Therapeutics, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company’s drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc (Ionis).
Receive News & Ratings for Akcea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.